The novel selective cardiac myosin activator omecamtiv mecarbil reduced a composite of a heart failure (HF) event or death from cardiovascular (CV) causes among patients with HF and a reduced ejection fraction (HFrEF) in the placebo-controlled phase 3 GALACTIC-HF trial.
However, there was no significant difference in the secondary outcome of death from CV causes, which led Amgen and Servier to terminate their collaboration with Cytokinetics to develop the drug. Cytokinetics still